Cancer cells have alteration in metabolic pathways as a result of oncogenes that promote tumor growth. NRF2 (nuclear factor erythroid-derived 2-related factor 2) works as a "master gene" that turns on stress response by increasing numerous antioxidants and pollutant-detoxifying genes to protect the lungs from variety of air pollutants such as diesel exhaust and cigarette smoke. However, researchers at the Johns Hopkins Bloomberg School of Public Health and others have found for the first time that NRF2 signaling also plays a role in the growth of tumor cells by altering metabolic pathways. The study is published in the July issue of the Journal of Clinical Investigation.
"Previously, we had reported that lung cancer cells, due to mutation in inhibitors of NRF2, hijack the stress response pathway to cause chemoresistance," said Shyam Biswal, PhD, lead investigator of the study and professor in the Department of Environmental Health Sciences at the Bloomberg School of Public Health. "With our latest study, we show how the NRF2 pathway reprograms glucose metabolism, leading to increased energy production and tumor cell proliferation. A better understanding of this process could lead to potential cancer treatments."
The Johns Hopkins study demonstrated an important and previously unrecognized role for the NRF2 transcription factor in regulating cell metabolism. Specifically, NRF2 regulates genes miR-1 and miR-206 to "reprogram" glucose metabolism through PPP (pentose phosphate pathway) and the TCA (tricarboxylic acid) cycle, and fatty acid synthesis. The study demonstrated that these enzyme pathways, working together in specific patterns, stimulated tumor growth. The researchers validated their findings through a series of in vitro experiments and studies involving mice.
"Although Nrf2 has been extensively studied as a target for chemoprevention, recent work from our group and others have highlighted the idea of developing inhibit
|Contact: Tim Parsons|
Johns Hopkins University Bloomberg School of Public Health